


**Product Name** : Navitoclax  
**Cat. No.** : PC-42277  
**CAS No.** : 923564-51-6  
**Molecular Formula** : C<sub>47</sub>H<sub>55</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>6</sub>S<sub>3</sub>  
**Molecular Weight** : 974.6127  
**Target** : Bcl-2  
**Solubility** : 10 mM in DMSO



## Biological Activity

Navitoclax (ABT-263) is a potent, orally bioavailable **Bcl-2** family inhibitor with  $K_i$  of <1 nM for Bcl-2, Bcl-xL, and Bcl-w.

Navitoclax (ABT-263) binds more weakly to Mcl-1 and A1 ( $K_i$  > 350 nM).

Navitoclax (ABT-263) disrupts Bcl-2/Bcl-xL interactions with pro-death proteins (e.g., Bim), induces apoptosis, shows cellular activity against a panel of human tumor cell lines ( $EC_{50}$  < 1  $\mu$ M).

Navitoclax (ABT-263) induces complete tumor regressions in xenograft models of NSCLA and ALL.

## References

Tse C, et al. *Cancer Res.* 2008 May 1;68(9):3421-8.

Shoemaker AR, et al. *Clin Cancer Res.* 2008 Jun 1;14(11):3268-77.

Ackler S, et al. *Mol Cancer Ther.* 2008 Oct;7(10):3265-74.

Shah OJ, et al. *Proc Natl Acad Sci U S A.* 2010 Jul 13;107(28):12634-9.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com